Certified CAR-T Center: Ruijin Hospital
Ruijin Hospital, founded in 1907 and affiliated with Shanghai Jiao Tong University School of Medicine, is a Tertiary Grade A public hospital located in Shanghai. With over 1,700 beds and a staff exceeding 6,000 as of 2022, it remains one of China’s most prestigious medical institutions.
Strengths & Hematology Ranking
Top-tier hematology research & innovation: According to Fudan University’s 2023 hematology hospital rankings, Ruijin ranks 3rd among China’s best hematology centers, boasting a reputation score of 8.453. The hospital leads in areas like hemophilia A gene therapy and development of novel anticoagulant reversal agents.
Historical breakthroughs: Professor Wang Zhenyi conducted the groundbreaking tretinoin therapy trial for acute promyelocytic leukemia (APL) at Ruijin in 1986—an innovation that transformed the prognosis for this leukemia subtype.
National-level standing: In broader health institution rankings (SCImago), Ruijin consistently ranks among China’s top research and innovation centers—ranking as high as 3rd in health sector performance (circa 2006) and 1st in Health (Shanghai) by 2024.
Clinical Excellence in CAR-T Therapy at Ruijin Hospital
As of March, 2024, Ruijin Hospital in Shanghai reached a significant milestone, its 100th patient with relapsed or refractory lymphoma achieved complete remission and was successfully discharged following commercial CAR-T cell therapy.
To date, the hospital’s CAR-T program has treated at least 116 patients, achieving a three-month complete remission rate of approximately 80% and a twelve-month rate of nearly 70%.
Ruijin has established a comprehensive CAR-T treatment framework that includes rigorous pre-treatment assessments, oversight by a multidisciplinary team (MDT), and structured long-term follow-up. The MDT brings together specialists in hematology, critical care, neurology, cardiology, infectious diseases, imaging, pathology, radiology, oncology, and other relevant fields to ensure the highest standards of patient care.
Notably, the first patient enrolled in China’s registered CAR-T clinical trial at Ruijin Hospital has maintained sustained complete remission for more than five years—now approaching the six-year mark—highlighting the therapy’s potential for durable, long-term cures.
What to expect when you come to Ruijing Hospital for CAR-T cell therapy?
Choosing CAR-T therapy at Ruijin Hospital means you’re in caring and experienced hands every step of the way. From your first visit, the hospital’s expert team will guide you through the entire process, answering your questions and making sure you feel comfortable and informed.
You’ll have access to some of the most advanced CAR-T treatments available today, often backed by the latest research and clinical trials. Your doctors and specialists will work together to create a treatment plan that’s just right for you, focusing on your unique health needs and safety.
During your treatment, you can expect close monitoring by a team ready to manage any side effects quickly and carefully. The hospital staff will keep you updated about what to expect, helping you understand the benefits and risks so you can feel confident about your care.
Even after your treatment, Ruijin Hospital will continue to support you with regular check-ups and follow-ups. They use modern tools, like digital communication platforms, to stay connected and make sure your recovery is going smoothly.
In short, Ruijin Hospital is committed to making your CAR-T therapy journey as smooth and positive as possible, with expert care and compassion at every step.
Patient Stories
Patient Voices: Their Stories, In Their Words
Why considering CAR T-cell therapy in China?
China has experienced remarkable growth in the field of medicine over the past few decades, reflecting its broader advancements in science and technology. The country has made substantial investments in healthcare infrastructure, research, and development, which have significantly improved its medical capabilities. Cutting-edge facilities, increased funding for biomedical research, and a focus on innovation have enabled China to make strides in various areas of medicine, including CAR T-cell therapy.
CAR T-cell therapy has seen substantial progress in China, with several therapies approved for treating blood cancers like lymphoma, acute lymphoblastic leukemia and multiple myeloma. The NMPA has streamlined approval processes, and domestic companies are actively developing new therapies and reducing costs. Research and clinical trials are vibrant, focusing on improving efficacy and managing side effects. China is making significant strides in expanding the availability and innovation of CAR T-cell therapies.
Expert Treatment
China has made significant strides in medical care and research, including advancements in CAR T-cell therapy.
Leader in CAR-T R&D
China’s rapid advancements in biotechnologies are establishing it as a leader in CAR T-cell therapy, ensuring effective treatments.
Quality & Affordable
China offers effective CAR T-cell therapies and other medical services with patient-friendly pricing and an accessible approach.
No Waiting Time
Timely treatment enhances recovery, reduces complications, and improves healthcare efficiency and patient satisfaction.
Share this
